Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Ronald Silver Sells 12,048 Shares

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) insider Ronald Silver sold 12,048 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $21,204.48. Following the completion of the sale, the insider now directly owns 279,655 shares of the company’s stock, valued at approximately $492,192.80. This represents a 4.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ironwood Pharmaceuticals Trading Up 3.2 %

Shares of NASDAQ IRWD opened at $1.94 on Thursday. The stock has a 50 day simple moving average of $3.63 and a 200-day simple moving average of $4.18. Ironwood Pharmaceuticals, Inc. has a 12-month low of $1.59 and a 12-month high of $15.70.

Wall Street Analyst Weigh In

Several research firms have recently commented on IRWD. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Craig Hallum lowered their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. Finally, JMP Securities lowered their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. RPO LLC acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $77,000. Geode Capital Management LLC lifted its position in Ironwood Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock worth $14,652,000 after purchasing an additional 13,028 shares during the period. Norges Bank acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter worth approximately $1,118,000. EntryPoint Capital LLC lifted its position in Ironwood Pharmaceuticals by 277.5% in the fourth quarter. EntryPoint Capital LLC now owns 62,913 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 46,248 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter worth approximately $107,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.